Detalhe da pesquisa
1.
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
Mult Scler
; 29(2): 221-235, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36433775
2.
Determinants of therapeutic lag in multiple sclerosis.
Mult Scler
; 27(12): 1838-1851, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33423618
3.
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis.
Mult Scler
; 27(5): 755-766, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32538713
4.
Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.
Mult Scler
; 26(13): 1765-1774, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31668127
5.
Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis.
Mult Scler
; 24(12): 1569-1577, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30234431
6.
Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.
Brain
; 136(Pt 12): 3609-17, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24142147
7.
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry.
Neurodegener Dis Manag
; 13(4): 215-221, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37287269